Avalia - Treatment Therapy for Solid Tumors
Avalia’s solid tumor preclinical program focusing on eradication of solid tumors has shown meaningful tumor regression and survival benefits in models of melanoma, glioblastoma and lung cancer and also in combination with market approved therapeutic agents and others in development.
-
Most popular related searches
Details
Our strategy is to use Avalia vaccines as a monotherapy to treat pre-malignant and early stage cancers. Avalia vaccines also have a role in combination therapies with other cancer fighting therapies for late stage cancers by strengthening or priming the body’s natural immune response to improve response rates of non-responder patients.
Unfortunately cancer continues to be the second leading cause of death globally. In 2015, there were approximately 8.8 million deaths from cancer. Avalia’s preclinical cancer program focuses on the development of therapeutic vaccines for the treatment of solid tumors and virus-driven cancers. Avalia’s vaccines elicit natural killer T cells to drive a potent and targeted immune response against tumors, a mechanism complementary to other treatment approaches
Customer reviews
No reviews were found for Avalia - Treatment Therapy for Solid Tumors. Be the first to review!